Improving Patient Experience with Insulin Infusion Sets
Annual Meeting Session on Demand
Effective dates for CE credit: 8/5/2015 – 8/5/2017
In 2011, an AADE white paper described best practices in selecting and using devices for continuous subcutaneous insulin infusion (CSII). Yet, even when best practices are observed, insulin delivery inaccuracies occur, leading to unexplained hyperglycemia. Recent studies indicate that partial interruptions of insulin flow, or silent occlusions, are one of several, largely unrecognized, insulin infusion‐set issues that pose a challenge to optimal diabetes control. Development of infusion‐set technology that specifically addresses silent occlusions is now under way, warranting formal discussion of the issue. This symposium will identify knowledge gaps surrounding silent occlusions and other infusion‐set issues affecting patients’ experience with CSII, and enumerate strategies for preventing inaccurate insulin delivery and optimizing treatment success.
This recording of a live presentation is a knowledge-based learning activity.
At the end of this presentation, the participant will be able to:
- Discuss how insulin infusion set failure may lead to unexplained hyperglycemia
- Evaluate features of insulin infusion sets taking into account specific patient needs
- Explain how factors of healthcare delivery affect insulin infusion set practices
This is a knowledge-based activities designed for individual or groups of diabetes educators, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants, MDs, and other health care providers interested in staying up to date on current practices of care for their patients with diabetes and other related conditions.
John Walsh, PA, CDTC
Diabetes Clinical Specialist
Advanced Metabolic Care and Research
Alison Evert, MS, RD, CDE
Coordinator Diabetes Education Programs
University of Washington Medical Center Endocrine and Diabetes Care Center
Phyllis Wolff-McDonagh, DNP, ANP, CPNP, CDE
Florida Health Care Plan Department of Endocrinology
This educational program is being supported by an independent educational grant from BD.
Continuing Education Credit
This educational program will provide 1.5 contact hours of continuing education credit. To successfully complete the program to earn CE credit, learners must view the recorded session in its entirety, complete any associated assessment activities, and submit an evaluation survey. A continuing education statement of credit will be provided online.
The American Association of Diabetes Educators is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational program will provide 1.5 contact hours of continuing education credit.
AADE is accredited as a provider of continuing nursing education by the California Board of Registered Nursing (CEP # 10977).
|Registered Dietitians |
The American Association of Diabetes Educators, (AM001) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program. Continuing Professional Education Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.
|Registered Pharmacists |
The American Association of Diabetes Educators is accredited bythe Accreditation Council for Pharmacy Education as a provider of continuingpharmacy education. This program provides 1.5 contact hours (0.15 CEUs) of continuing education credit.
ACPE Universal Program Number: 0069-9999-15-196-H01-P
Effective Dates: 8/5/2015 – 8/5/2017
It is the policy of the American Association of Diabetes Educators to require that anyone who has an opportunity to affect continuing education activities content (e.g. authors, presenters and program planners) with products or services from a commercial interest with which s/he has financial relationships, discloses those financial relationship/s with commercial entities to participants.
Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant disclosures (or lack thereof) among educational activity faculty and planners are as follows:
- John Walsh, PA, CDTC, Advanced Metabolic Care and Research, has relevant financial disclosures to report: Advisory board member Companion Diabetes and Convatec; Book sales All insulin pump companies; Consultant Abbott, Acon Laboratories, Bayer, BD Medical – Diabetes Care, Companion Diabetes, Roche, Tandem Diabetes; Pump trainer Accu‐Chek, Animas, Medtronic, OmniPod, Tandem Diabetes; Speaker’s bureau Animas, BD Medical − Diabetes Care, Sanofi, Tandem Diabetes; Sub‐investigator Animas, Bayer, Dexcom, Eli Lilly and Company, GlaxoSmithKline, Medtronic, Novo Nordisk.
- Alison Evert, MS, RD, CDE, University of Washington Medical Center Endocrine and Diabetes Care Center, has no relevant financial disclosures to report.
- Phyllis Wolff-McDonagh, DNP, ANP, CPNP, CDE, Florida Health Care Plan Department of Endocrinology, has relevant financial disclosures to report: Consultant BD Medical – Diabetes Care
- Nancy Stonis, AADE, Chicago, IL, has no relevant financial disclosures to report.
- Jackie Bellan, AADE, Chicago, IL, has no relevant financial disclosures to report.
- Leah Johnson, AADE, Chicago, IL, has no relevant financial disclosures to report.
The approval of this educational offering by the AADE does not imply endorsement of specific therapies, treatments, or products discussed in the presentations.
Originally presented on: 8/5/2015
Expiration date: 8/5/2017
You will have access to this learning activity for a period of six months after you enroll, or whenever the activity's CE credits expire (whichever comes first).